Vanderbilt-Ingram Cancer Center

None Provided.

Criteria
 Inclusion Criteria:

 • Cytologically or histologically confirmed pancreatic adenocarcinoma (excluding islet cell or ampullary tumors) that is metastatic or unresectable

 • Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

 • Patients may have received prior chemotherapy for advanced disease as long as it did not include gemcitabine; if patients received prior adjuvant therapy including gemcitabine, patients must be > 6 months from the last dose of gemcitabine; patients must have recovered from side effects of prior therapy to grade =< 1 as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0

 • Patients may have received prior radiation presuming > 4 weeks since last dose and measurable disease outside the radiation field

 • Eastern Cooperative Oncology Group (ECOG) performance status =< 1

 • Anticipated life expectancy of greater than 3 months

 • Leukocytes >= 3,000/mcL

 • Absolute neutrophil count >= 1,500/mcL

 • Platelets >= 100,000/mcL

 • Total bilirubin =< 2.5 x institutional upper limit of normal (ULN)

 • Aspartate aminotransferase (AST) (serum glutamic pyruvate transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal OR =< 5 X institutional upper limit of normal when liver metastases are present

 • Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

 • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

 • Ability to understand and the willingness to sign a written informed consent document

 • Patients must be able to swallow pills

 Exclusion Criteria:

 • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier (with the exception of alopecia and neuropathy); no radiation is allowed on study

 • Patients who are receiving any other investigational agents

 • Major surgical procedure within 4 weeks of treatment

 • Patients with known brain metastases

 • History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib, erlotinib or gemcitabine

 • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

 • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib or dasatinib

 • Patients with immune deficiency are excluded

 • Patients on potent cytochrome P450 3A4 (CYP3A4) inducers and inhibitors

 • Malabsorption syndrome or other condition that would interfere with intestinal absorption

 • Other active malignancy

 • Human immunodeficiency virus (HIV) positive patients who are on combination antiretroviral therapy

 • Myocardial infarction or ventricular tachyarrhythmia within 6 months

 • Prolonged corrected QT interval (QTc) > 480 msec (Fridericia correction)

 • Known ejection faction less than institutional normal

 • Major conduction abnormality (unless a cardiac pacemaker is present)